TY - JOUR
T1 - Efficacy of tegafur/uracil plus oral leucovorin therapy for advanced or recurrent colorectal cancer
AU - Kabashima, Akira
AU - Sakaguchi, Yoshihisa
AU - Okita, Keishi
AU - Yamamura, Shinji
AU - Ojima, Yasutomo
AU - Nishizaki, Takashi
AU - Tashiro, Hideya
AU - Matsuzaka, Toshimitsu
PY - 2005/11
Y1 - 2005/11
N2 - The aim of this study was to evaluate the efficacy of tegafur/uracil (UFT) and oral Leucovorin(UZEL) in patients with advanced or recurrent colorectal cancer. Eight patients were treated with UFT/UZEL therapy as a first-line chemotherapy. UFT(300 mg/m(2)/day) and UZEL (75 mg/body/day) were administered orally for 28 consecutive days followed by a 7-day rest period, and this schedule was repeated every 5 weeks. The mean of treatment courses given to the patients was 7.6. Tumor response was evaluated in 7 patients who had assessable lesions, and the response rate was 86% (6 PR and 1 NC). Adverse reactions of grade 3 were observed in 2 patients (25%), but toxicity did not cause a discontinuance of treatment in any case. The UFT/UZEL therapy was considered to be a promising regimen for advanced or recurrent colorectal cancer from a standpoint of effect, safety and QOL of patients.
AB - The aim of this study was to evaluate the efficacy of tegafur/uracil (UFT) and oral Leucovorin(UZEL) in patients with advanced or recurrent colorectal cancer. Eight patients were treated with UFT/UZEL therapy as a first-line chemotherapy. UFT(300 mg/m(2)/day) and UZEL (75 mg/body/day) were administered orally for 28 consecutive days followed by a 7-day rest period, and this schedule was repeated every 5 weeks. The mean of treatment courses given to the patients was 7.6. Tumor response was evaluated in 7 patients who had assessable lesions, and the response rate was 86% (6 PR and 1 NC). Adverse reactions of grade 3 were observed in 2 patients (25%), but toxicity did not cause a discontinuance of treatment in any case. The UFT/UZEL therapy was considered to be a promising regimen for advanced or recurrent colorectal cancer from a standpoint of effect, safety and QOL of patients.
UR - http://www.scopus.com/inward/record.url?scp=32944461470&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32944461470&partnerID=8YFLogxK
M3 - Article
C2 - 16282730
AN - SCOPUS:32944461470
SN - 0385-0684
VL - 32
SP - 1935
EP - 1938
JO - Gan to kagaku ryoho. Cancer & chemotherapy
JF - Gan to kagaku ryoho. Cancer & chemotherapy
IS - 12
ER -
